Modulatory activity of soluble beta amyloid on HPA axis function in rats

Current Pharmaceutical Design

Volumn 20, Issue 15, 2014, Pages 2539-2546

  Morgese, Maria Grazia ^a   Tucci, Paolo ^a   Colaianna, Marilena ^a   Zotti, Margherita ^a   Cuomo, Vincenzo ^b   Schiavone, Stefania ^c   Trabace, Luigia ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Amygdala; Corticosterone; CRF; Hippocampus; HPA; Noradrenaline; Passive avoidance task; Prefrontal cortex; Soluble beta amyloid; Stress

Indexed keywords

AMYLOID BETA PROTEIN; CORTICOSTERONE; CORTICOTROPIN RELEASING FACTOR; HYDROCORTISONE; NORADRENALIN; SOLUBLE BETA AMYLOID; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYGDALOID NUCLEUS; ANHEDONIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN FUNCTION; BRAIN REGION; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; EX VIVO STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; MEMORY CONSOLIDATION; NONHUMAN; NORADRENERGIC SYSTEM; PASSIVE AVOIDANCE TEST; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SHORT TERM MEMORY; SUCROSE PREFERENCE TEST; ANIMAL; AVOIDANCE BEHAVIOR; BLOOD; BRAIN; DRUG EFFECTS; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; WISTAR RAT;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; AVOIDANCE LEARNING; BRAIN; CORTICOSTERONE; CORTICOTROPIN-RELEASING HORMONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; PITUITARY-ADRENAL SYSTEM; RATS; RATS, WISTAR;

EID: 84903711022     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990500     Document Type: Article

References (82)

1. Hong S, Quintero-Monzon O, Ostaszewski BL, et al. Dynamic analysis of amyloid beta-protein in behaving mice reveals opposing changes in ISF versus parenchymal Abeta during age-related plaque formation. J Neurosci 2011; 31(44): 15861-9.
2. Walsh DM, Selkoe DJ. A beta oligomers-a decade of discovery. J Neurochem 2007; 101(5): 1172-84.
3. Jellinger KA, Bancher C. Neuropathology of Alzheimer's disease: a critical update. J Neural Transmission 1998; 54: 77-95.
4. Perez RG, Soriano S, Hayes JD, et al. Mutagenesis identifies new signals for beta-amyloid precursor protein endocytosis, turnover, and the generation of secreted fragments, including Abeta42. J Biological Chem 1999; 274(27): 18851-6.
5. LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci 2007; 8(7): 499-509.
6. Wirths O, Multhaup G, Bayer TA. A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide--the first step of a fatal cascade. J Neurochem 2004; 91(3): 513-20.
7. Tampellini D, Rahman N, Gallo EF, et al. Synaptic activity reduces intraneuronal Abeta, promotes APP transport to synapses, and protects against Abeta-related synaptic alterations. J Neurosci 2009; 29(31): 9704-13.
8. Tampellini D, Capetillo-Zarate E, Dumont M, et al. Effects of synaptic modulation on beta-amyloid, synaptophysin, and memory performance in Alzheimer's disease transgenic mice. J Neurosci 2010; 30(43): 14299-304.
9. Demuro A, Mina E, Kayed R, Milton SC, Parker I, Glabe CG. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biological Chem 2005; 280(17): 17294-300.
10. Demuro A, Parker I, Stutzmann GE. Calcium signaling and amyloid toxicity in Alzheimer disease. J Biological Chem 2010; 285(17): 12463-8.
11. Preda S, Govoni S, Lanni C, et al. Acute beta-amyloid administration disrupts the cholinergic control of dopamine release in the nucleus accumbens. Neuropsychopharmacology 2008; 33(5): 1062-70.
12. Mura E, Zappettini S, Preda S, et al. Dual effect of beta-amyloid on alpha7 and alpha4beta2 nicotinic receptors controlling the release of glutamate, aspartate and GABA in rat hippocampus. PloS one 2012; 7(1): e29661.
13. Mura E, Lanni C, Preda S, et al. Beta-amyloid: a disease target or a synaptic regulator affecting age-related neurotransmitter changes? Current pharmaceutical design 2010; 16(6): 672-83.
14. Mura E, Preda S, Govoni S, et al. Specific neuromodulatory actions of amyloid-beta on dopamine release in rat nucleus accumbens and caudate putamen. J Alzheimers Dis 2010; 19(3): 1041-53.
15. Gonzalo-Ruiz A, Gonzalez I, Sanz-Anquela JM. Effects of betaamyloid protein on serotoninergic, noradrenergic, and cholinergic markers in neurons of the pontomesencephalic tegmentum in the rat. J Chem neuroanatom 2003; 26(3): 153-69.
16. Egashira N, Iwasaki K, Takashima A, et al. Altered depressionrelated behavior and neurochemical changes in serotonergic neurons in mutant R406W human tau transgenic mice. Brain Res 2005; 1059(1): 7-12.
17. Geerlings MI, den Heijer T, Koudstaal PJ, Hofman A, Breteler MM. History of depression, depressive symptoms, and medial temporal lobe atrophy and the risk of Alzheimer disease. Neurology 2008; 70(15): 1258-64.
18. Aznar S, Knudsen GM. Depression and Alzheimer's disease: is stress the initiating factor in a common neuropathological cascade? J Alzheimers Dis 2011; 23(2): 177-93.
19. Colaianna M, Tucci P, Zotti M, et al. Soluble beta amyloid(1-42): a critical player in producing behavioural and biochemical changes evoking depressive-related state? Br J Pharmacol 2010; 159(8): 1704-15.
20. Pomara N, Sidtis JJ. Brain neurotoxic amyloid-beta peptides: their potential role in the pathophysiology of depression and as molecular therapeutic targets. Br J Pharmacol 2010; 161(4): 768-70.
21. Kang JE, Cirrito JR, Dong H, Csernansky JG, Holtzman DM. Acute stress increases interstitial fluid amyloid-beta via corticotropin-releasing factor and neuronal activity. Proc Natl Acad Sci USA 2007; 104(25): 10673-8.
22. Hoogendijk WJ, Meynen G, Endert E, Hofman MA, Swaab DF. Increased cerebrospinal fluid cortisol level in Alzheimer's disease is not related to depression. Neurobiol Aging 2006; 27(5): 780 e1-e2.
23. Swaab DF, Raadsheer FC, Endert E, Hofman MA, Kamphorst W, Ravid R. Increased cortisol levels in aging and Alzheimer's disease in postmortem cerebrospinal fluid. J Neuroendocrinol 1994; 6(6): 681-7.
24. Green KN, Billings LM, Roozendaal B, McGaugh JL, LaFerla FM. Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease. J Neurosci 2006; 26(35): 9047-56.
25. Itoi K, Sugimoto N, Suzuki S, et al. Targeting of locus ceruleus noradrenergic neurons expressing human interleukin-2 receptor alpha-subunit in transgenic mice by a recombinant immunotoxin anti-Tac(Fv)-PE38: a study for exploring noradrenergic influence upon anxiety-like and depression-like behaviors. J Neurosci 2011; 31(16): 6132-9.
26. Wang D, Govindaiah G, Liu R, De Arcangelis V, Cox CL, Xiang YK. Binding of amyloid beta peptide to beta2 adrenergic receptor induces PKA-dependent AMPA receptor hyperactivity. Faseb J 2010; 24(9): 3511-21.
27. Wang D, Yuen EY, Zhou Y, Yan Z, Xiang YK. Amyloid beta peptide-(1-42) induces internalization and degradation of beta2 adrenergic receptors in prefrontal cortical neurons. J Biological Chem 2011; 286(36): 31852-63.
28. Mello AF, Mello MF, Carpenter LL, Price LH. Update on stress and depression: the role of the hypothalamic-pituitary-adrenal (HPA) axis. Rev Bras Psiquiatr 2003; 25(4): 231-8.
29. Harvey BH, Brand L, Jeeva Z, Stein DJ. Cortical/hippocampal monoamines, HPA-axis changes and aversive behavior following stress and restress in an animal model of post-traumatic stress disorder. Physiol Behavior 2006; 87(5): 881-90.
30. van Stegeren AH, Wolf OT, Everaerd W, Scheltens P, Barkhof F, Rombouts SA. Endogenous cortisol level interacts with noradrenergic activation in the human amygdala. Neurobiol Learning Memory 2007; 87(1): 57-66.
31. Trabace L, Kendrick KM, Castrignano S, et al. Soluble amyloid beta1-42 reduces dopamine levels in rat prefrontal cortex: relationship to nitric oxide. Neuroscience 2007; 147(3): 652-63.
32. Paxinos G, Watson CRR. The Rat Brain in Stereotaxic Coordinates: Elsevier Academic Press 1998.
33. Monteggia LM, Luikart B, Barrot M, et al. Brain-derived neurotrophic factor conditional knockouts show gender differences in depression-related behaviors. Biological Psychiatry 2007; 61(2): 187-97.
34. Katz RJ. Animal model of depression: pharmacological sensitivity of a hedonic deficit. Pharmacology, biochemistry, and behavior 1982; 16(6): 965-8.
35. Ennaceur A, Delacour J. A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behavioural Brain Res 1988; 31(1): 47-59.
36. Willner P, Towell A, Sampson D, Sophokleous S, Muscat R. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology 1987; 93(3): 358-64.
37. Muscat R, Papp M, Willner P. Reversal of stress-induced anhedonia by the atypical antidepressants, fluoxetine and maprotiline. Psychopharmacology 1992; 109(4): 433-8.
38. Muscat R, Willner P. Suppression of sucrose drinking by chronic mild unpredictable stress: a methodological analysis. Neuroscience and biobehavioral reviews 1992; 16(4): 507-17.
39. Ferry B, McGaugh JL. Clenbuterol administration into the basolateral amygdala post-training enhances retention in an inhibitory avoidance task. Neurobiol Learning Memory 1999; 72(1): 8-12.
40. Gallagher M, Kapp BS. Effect of phentolamine administration into the amygdala complex of rats on time-dependent memory processes. Behavioral and neural biology 1981; 31(1): 90-5.
41. Ferry B, Roozendaal B, McGaugh JL. Basolateral amygdala noradrenergic influences on memory storage are mediated by an interaction between beta-and alpha1-adrenoceptors. J Neurosci 1999; 19(12): 5119-23.
42. Debiec J, Bush DE, LeDoux JE. Noradrenergic enhancement of reconsolidation in the amygdala impairs extinction of conditioned fear in rats--a possible mechanism for the persistence of traumatic memories in PTSD. Depression and anxiety 2011; 28(3): 186-93.
43. Johnson LR, Hou M, Prager EM, Ledoux JE. Regulation of the Fear Network by Mediators of Stress: Norepinephrine Alters the Balance between Cortical and Subcortical Afferent Excitation of the Lateral Amygdala. Frontiers in behavioral neuroscience 2011; 5: 23.
44. Wong DL, Tai TC, Wong-Faull DC, et al. Epinephrine: A Shortand Long-Term Regulator of Stress and Development of Illness: A Potential New Role for Epinephrine in Stress. Cellular Molecular Neurobiol 2011.
45. McReynolds JR, Donowho K, Abdi A, McGaugh JL, Roozendaal B, McIntyre CK. Memory-enhancing corticosterone treatment increases amygdala norepinephrine and Arc protein expression in hippocampal synaptic fractions. Neurobiol Learning Memory 2010; 93(3): 312-21.
46. Roozendaal B, McGaugh JL. Amygdaloid nuclei lesions differentially affect glucocorticoid-induced memory enhancement in an inhibitory avoidance task. Neurobiol Learning memory 1996; 65(1): 1-8.
47. Roozendaal B, Portillo-Marquez G, McGaugh JL. Basolateral amygdala lesions block glucocorticoid-induced modulation of memory for spatial learning. Behavioral neuroscience 1996; 110(5): 1074-83.
48. Cahill L, Gorski L, Le K. Enhanced human memory consolidation with post-learning stress: interaction with the degree of arousal at encoding. Learning & memory (Cold Spring Harbor, NY 2003; 10(4): 270-4.
49. Cahill L, Alkire MT. Epinephrine enhancement of human memory consolidation: interaction with arousal at encoding. Neurobiol Learning Memory 2003; 79(2): 194-8.
50. Dong H, Csernansky JG. Effects of stress and stress hormones on amyloid-beta protein and plaque deposition. J Alzheimers Dis 2009; 18(2): 459-69.
51. Cirrito JR, Yamada KA, Finn MB, et al. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 2005 Dec 22; 48(6): 913-22.
52. Cirrito JR, Kang JE, Lee J, et al. Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron 2008; 58(1): 42-51.
53. Liu J, Yu B, Neugebauer V, et al. Corticotropin-releasing factor and Urocortin I modulate excitatory glutamatergic synaptic transmission. J Neurosci 2004; 24(16): 4020-9.
54. Schmolesky MT, De Ruiter MM, De Zeeuw CI, Hansel C. The neuropeptide corticotropin-releasing factor regulates excitatory transmission and plasticity at the climbing fibre-Purkinje cell synapse. Eur J Neurosci 2007; 25(5): 1460-6.
55. Harkany T, Abraham I, Timmerman W, et al. beta-amyloid neurotoxicity is mediated by a glutamate-triggered excitotoxic cascade in rat nucleus basalis. The European journal of neuroscience 2000; 12(8): 2735-45.
56. Nakagami Y, Oda T. Glutamate exacerbates amyloid beta1-42-induced impairment of long-term potentiation in rat hippocampal slices. Japanese journal of pharmacology 2002; 88(2): 223-6.
57. Snyder EM, Nong Y, Almeida CG, et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nature neuroscience 2005; 8(8): 1051-8.
58. Tyszkiewicz JP, Yan Z. beta-Amyloid peptides impair PKCdependent functions of metabotropic glutamate receptors in prefrontal cortical neurons. Journal of neurophysiology 2005; 93(6): 3102-11.
59. Coussens CM, Kerr DS, Abraham WC. Glucocorticoid receptor activation lowers the threshold for NMDA-receptor-dependent homosynaptic long-term depression in the hippocampus through activation of voltage-dependent calcium channels. Journal of neurophysiology 1997; 78(1): 1-9.
60. Krugers HJ, Goltstein PM, van der Linden S, Joels M. Blockade of glucocorticoid receptors rapidly restores hippocampal CA1 synaptic plasticity after exposure to chronic stress. The European journal of neuroscience 2006; 23(11): 3051-5.
61. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008; 9(1): 46-56.
62. Sanz JM, Chiozzi P, Idzko M, et al. Activation of microglia by amyloid β requires P2X7 receptor expression. J Immunol 2009; 182(7): 4378-85.
63. Csolle C, Ando RD, Kittel A, et al. The absence of P2X7 receptors (P2rx7) on non-haematopoietic cells leads to selective alteration in mood-related behaviour with dysregulated gene expression and stress reactivity in mice. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 2012; 16: 1-21.
64. Jeanneteau FD, Lambert WM, Ismaili N, et al. BDNF and glucocorticoids regulate corticotrophin-releasing hormone (CRH) homeostasis in the hypothalamus. Proceedings of the National Academy of Sciences of the United States of America 2012; 109(4): 1305-10.
65. Dong H, Yuede CM, Yoo HS, et al. Corticosterone and related receptor expression are associated with increased beta-amyloid plaques in isolated Tg2576 mice. Neuroscience 2008; 155(1): 154-63.
66. Csernansky JG, Dong H, Fagan AM, et al. Plasma cortisol and progression of dementia in subjects with Alzheimer-type dementia. The American journal of psychiatry 2006; 163(12): 2164-9.
67. Souza-Talarico JN, Caramelli P, Nitrini R, Chaves EC. Effect of cortisol levels on working memory performance in elderly subjects with Alzheimer's disease. Arquivos de neuro-psiquiatria 2008; 66(3B): 619-24.
68. Peskind ER, Wilkinson CW, Petrie EC, Schellenberg GD, Raskind MA. Increased CSF cortisol in AD is a function of APOE genotype. Neurology 2001; 56(8): 1094-8.
69. Weiner MF, Vobach S, Olsson K, Svetlik D, Risser RC. Cortisol secretion and Alzheimer's disease progression. Biological psychiatry 1997; 42(11): 1030-8.
70. Davis KL, Davis BM, Greenwald BS, et al. Cortisol and Alzheimer's disease, I: Basal studies. The American journal of psychiatry 1986; 143(3): 300-5.
71. Rasmuson S, Nasman B, Carlstrom K, Olsson T. Increased levels of adrenocortical and gonadal hormones in mild to moderate Alzheimer's disease. Dementia and geriatric cognitive disorders 2002; 13(2): 74-9.
72. Swanwick GR, Kirby M, Bruce I, et al. Hypothalamic-pituitaryadrenal axis dysfunction in Alzheimer's disease: lack of association between longitudinal and cross-sectional findings. The American journal of psychiatry 1998; 155(2): 286-9.
73. Umegaki H, Ikari H, Nakahata H, et al. Plasma cortisol levels in elderly female subjects with Alzheimer's disease: a cross-sectional and longitudinal study. Brain research 2000; 881(2): 241-3.
74. Pedersen WA, Wan R, Mattson MP. Impact of aging on stressresponsive neuroendocrine systems. Mechanisms of ageing and development 2001; 122(9): 963-83.
75. Nasman B, Olsson T, Viitanen M, Carlstrom K. A subtle disturbance in the feedback regulation of the hypothalamic-pituitaryadrenal axis in the early phase of Alzheimer's disease. Psychoneuroendocrinology 1995; 20(2): 211-20.
76. Swaab DF, Bao AM, Lucassen PJ. The stress system in the human brain in depression and neurodegeneration. Ageing research reviews 2005; 4(2): 141-94.
77. Imbimbo BP, Giardina GA. gamma-secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes. Current topics in medicinal chemistry 2011; 11(12): 1555-70.
78. Abdul-Hay SO, Edirisinghe P, Thatcher GR. Selective modulation of amyloid-beta peptide degradation by flurbiprofen, fenofibrate, and related compounds regulates Abeta levels. Journal of neurochemistry 2009; 111(3): 683-95.
79. Abdul-Hay SO, Luo J, Ashghodom RT, Thatcher GR. NOflurbiprofen reduces amyloid-beta, is neuroprotective in cell culture, and enhances cognition in response to cholinergic blockade. Journal of neurochemistry 2009; 111(3): 766-76.
80. Henley DB, May PC, Dean RA, Siemers ER. Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease. Expert opinion on pharmacotherapy 2009; 10(10): 1657-64.
81. Huang CW, Lui CC, Chang WN, Lu CH, Wang YL, Chang CC. Elevated basal cortisol level predicts lower hippocampal volume and cognitive decline in Alzheimer's disease. J Clin Neurosci 2009; 16(10): 1283-6.
82. Takeda S, Sato N, Rakugi H, Morishita R. Plasma beta-amyloid as potential biomarker of Alzheimer disease: possibility of diagnostic tool for Alzheimer disease. Molecular bioSystems 2010; 6(10): 1760-6.